Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;61(10):e70142.
doi: 10.1111/ejn.70142.

Nano-Chaperones: Bridging Therapeutics for Amyloid Aggregation in Alzheimer's Disease and Type-2 Diabetes Mellitus

Faiza Siddiqui  1 , Pooja Mishra  1 , Sheeba Khanam  1 , Sachin Ranjan  1 , Pravej Alam  2 , Thamer Albalawi  2 , Salman Khan  1 , Snober S Mir  1
Affiliations
Review

Nano-Chaperones: Bridging Therapeutics for Amyloid Aggregation in Alzheimer's Disease and Type-2 Diabetes Mellitus

Faiza Siddiqui et al. Eur J Neurosci. 2025 May.

Abstract

Nano-chaperones represent an innovative therapeutic approach targeting amyloid aggregation in Alzheimer's disease (AD) and Type-2 diabetes mellitus (T2DM), two diseases linked by similar pathogenic mechanisms involving protein misfolding and insulin resistance. Current treatments primarily address symptoms, yet nano-chaperones can potentially intervene at the molecular level by mimicking natural chaperone proteins to prevent or reverse amyloid aggregation. In AD, nano-chaperones target amyloid-beta (Aβ) peptides, reducing neurotoxicity and preserving neuronal function, while in T2DM, they inhibit islet amyloid polypeptide (IAPP) aggregation, alleviating cytotoxic stress on pancreatic β-cells. These nanoparticles exhibit a dual capacity for cellular penetration and selectivity in interacting with misfolded proteins, showing promise in mitigating the shared amyloidogenic pathways of both diseases. Preclinical studies have demonstrated significant reductions in amyloid toxicity with potential applications in crossing the blood-brain barrier (BBB) to enhance central nervous system (CNS) delivery. Nano-chaperones transformative role in developing multi-targeted precision therapies for complex diseases is highlighted, underscoring their capacity to modulate disease progression through targeted biomimetic interactions. Nano-chaperone designs for clinical application focus on enhancing therapeutic efficacy and safety. This innovative approach may redefine treatment paradigms for amyloid-related diseases, offering a new frontier in personalized medicine.

Keywords: alzheimer's disease; amyloid beta; islet amyloid polypeptide; nano‐chaperones; type 2 diabetes mellitus.

PubMed Disclaimer

References

    1. Aaboe, K., F. K. Knop, T. Vilsbøll, et al. 2010. “Twelve Weeks Treatment With the DPP‐4 Inhibitor, Sitagliptin, Prevents Degradation of Peptide YY and Improves Glucose and Non‐Glucose Induced Insulin Secretion in Patients With Type 2 Diabetes Mellitus.” Diabetes, Obesity and Metabolism 12: 323–333.
    1. Ahmad, S., M. F. A. Ahmad, S. Khan, et al. 2024. “Exploring Aldose Reductase Inhibitors as Promising Therapeutic Targets for Diabetes‐Linked Disabilities.” International Journal of Biological Macromolecules 280: 135761.
    1. AlAnazi, F. H., H. M. Al‐kuraishy, A. I. Al‐Gareeb, et al. 2023. “Effects of Neprilysin and Neprilysin Inhibitors on Glucose Homeostasis: Controversial Points and a Promising Arena.” Journal of Diabetes 15: 397–408.
    1. Al‐Kuraishy, H. M., A. I. Al‐Gareeb, H. M. Saad, and G. E.‐S. Batiha. 2023. “Long‐Term Use of Metformin and Alzheimer's Disease: Beneficial or Detrimental Effects.” Inflammopharmacology 31: 1107–1115.
    1. Almeida, Z. L., and R. M. M. Brito. 2020. “Structure and Aggregation Mechanisms in Amyloids.” Molecules 25: 1195.

MeSH terms

LinkOut - more resources